SARS-CoV-2, the etiologic
agent of the COVID-19 pandemic, emerged
as the cause of a global crisis. Rapid and reliable clinical diagnosis
is essential for effectively controlling transmission. The gold standard
assay for SARS-CoV-2 identification is the highly sensitive real-time
quantitative polymerase chain reaction (RT-qPCR); however, this assay
depends on specialized reagents and may suffer from false results.
Thus, additional assays based on different approaches could be beneficial.
Here, we present a novel method for SARS-CoV-2 identification based
on mass spectrometry. The approach we implemented combines a multistep
procedure for the rational down-selection of a set of reliable markers
out of all optional
in silico
derived tryptic peptides
in viral proteins, followed by monitoring of peptides derived from
tryptic digests of purified proteins, cell-cultured SARS-CoV-2, and
nasopharyngeal (NP) swab matrix spiked with the virus. The marker
selection was based on specificity to SARS-CoV-2 and on analytical
parameters including sensitivity, linearity, and reproducibility.
The final assay is based on six unique and specific peptide markers
for SARS-CoV-2 identification. The simple and rapid (2.5 h) protocol
we developed consists of virus heat inactivation and denaturation,
tryptic digestion, and identification of the selected markers by liquid
chromatography coupled to high-resolution mass spectrometry (LC-MS/MS).
The developed assay enabled the identification of 10
4
PFU/mL
SARS-CoV-2 spiked into buffer. Finally, the assay was successfully
applied to 16 clinical samples diagnosed by RT-qPCR, achieving 94%
concordance with the current gold standard assay. To conclude, the
novel MS-based assay described here is specific, rapid, simple, and
is believed to provide a complementary assay to the RT-qPCR method.